Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features

被引:18
|
作者
Rommasi, Foad [1 ]
Nasiri, Mohammad Javad [2 ]
Mirsaeidi, Mehdi [3 ]
机构
[1] Shahid Beheshti Univ, Fac Life Sci & Biotechnol, Tehran, Iran
[2] Shahid Beheshti Univ Med Sci, Sch Med, Dept Microbiol, Tehran, Iran
[3] Univ Miami, Miller Sch Med, Dept Pulm & Crit Care, Miami, FL 33136 USA
关键词
SARS-CoV-2; Pathophysiology; COVID-19; treatment; Inflammatory responses; Immunosuppressive agents; Cytokine storm; NECROSIS-FACTOR-ALPHA; CORONAVIRUS DISEASE 2019; RHEUMATOID-ARTHRITIS; CLINICAL PHARMACOKINETICS; RECEPTOR ANTAGONIST; IN-VITRO; ABSOLUTE BIOAVAILABILITY; COLCHICINE THERAPY; CYTOKINE STORM; MELATONIN;
D O I
10.1007/s11010-021-04325-9
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The novel coronavirus pandemic has emerged as one of the significant medical-health challenges of the current century. The World Health Organization has named this new virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since the first detection of SARS-CoV-2 in November 2019 in Wuhan, China, physicians, researchers, and others have made it their top priority to find drugs and cures that can effectively treat patients and reduce mortality rates. The symptoms of Coronavirus Disease 2019 (COVID-19) include fever, dry cough, body aches, and anosmia. Various therapeutic compounds have been investigated and applied to mitigate the symptoms in COVID-19 patients and cure the disease. Degenerative virus analyses of the infection incidence and COVID-19 have demonstrated that SARS-CoV-2 penetrates the pulmonary alveoli's endothelial cells through Angiotensin-Converting Enzyme 2 (ACE2) receptors on the membrane, stimulates various signaling pathways and causes excessive secretion of cytokines. The continuous triggering of the innate and acquired immune system, as well as the overproduction of pro-inflammatory factors, cause a severe condition in the COVID-19 patients, which is called "cytokine storm". It can lead to acute respiratory distress syndrome (ARDS) in critical patients. Severe and critical COVID-19 cases demand oxygen therapy and mechanical ventilator support. Various drugs, including immunomodulatory and immunosuppressive agents (e.g., monoclonal antibodies (mAbs) and interleukin antagonists) have been utilized in clinical trials. However, the studies and clinical trials have documented diverging findings, which seem to be due to the differences in these drugs' possible mechanisms of action. These drugs' mechanism of action generally includes suppressing or modulating the immune system, preventing the development of cytokine storm via various signaling pathways, and enhancing the blood vessels' diameter in the lungs. In this review article, multiple medications from different drug families are discussed, and their possible mechanisms of action are also described.
引用
收藏
页码:711 / 726
页数:16
相关论文
共 50 条
  • [31] Mechanism of action of immunomodulatory agents in multiple myeloma
    Thomas Reske
    Mariateresa Fulciniti
    Nikhil C. Munshi
    Medical Oncology, 2010, 27 : 7 - 13
  • [32] Mechanism of action of immunomodulatory agents in multiple myeloma
    Reske, Thomas
    Fulciniti, Mariateresa
    Munshi, Nikhil C.
    MEDICAL ONCOLOGY, 2010, 27 : 7 - 13
  • [33] Pharmacological mechanism of action of Lianhua Qingwen in the treatment of COVID-19 and facial neuritis
    Li, Guang-Jin
    Hao, Zhi-Hong
    Wang, Han-Jing
    Wang, Chen
    Liu, Da-Wei
    Chen, Liang
    Sun, Yan
    WORLD JOURNAL OF OTORHINOLARYNGOLOGY-HEAD & NECK SURGERY, 2025, 11 (01): : 102 - 115
  • [34] Pharmacological mechanism of action of Lianhua Qingwen in the treatment of COVID-19 and facial neuritis
    Li GuangJin
    Hao ZhiHong
    Wang HanJing
    Wang Chen
    Liu DaWei
    Chen Liang
    Sun Yan
    世界耳鼻咽喉头颈外科杂志(英文), 2025, 11 (01)
  • [35] Treatment of Cytokine Storm in COVID-19 Patients With Immunomodulatory Therapy
    Yessayan, Lenar
    Szamosfalvi, Balazs
    Napolitano, Lena
    Singer, Benjamin
    Kurabayashi, Katsuo
    Song, Yujing
    Westover, Angela
    Humes, H. David
    ASAIO JOURNAL, 2020, 66 (10) : 1079 - 1083
  • [36] Advances in the possible treatment of COVID-19: A review
    Chibber, Pankaj
    Haq, Syed Assim
    Ahmed, Irfan
    Andrabi, Nusrit Iqbal
    Singh, Gurdarshan
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2020, 883
  • [37] Tetracycline and viruses: a possible treatment for COVID-19?
    Jesús A. Mosquera-Sulbaran
    Hugo Hernández-Fonseca
    Archives of Virology, 2021, 166 : 1 - 7
  • [38] Antiplatelet agents for the treatment of adults with COVID-19
    Fischer, Anna-Lena
    Messer, Sarah
    Riera, Rachel
    Martimbianco, Ana Luiza C.
    Stegemann, Miriam
    Estcourt, Lise J.
    Weibel, Stephanie
    Monsef, Ina
    Andreas, Marike
    Pacheco, Rafael L.
    Skoetz, Nicole
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2023, (07):
  • [39] Favipiravir: A Possible Pharmaceutical Treatment for COVID-19
    Yanai, Hidekatsu
    JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2020, 10 (02) : 33 - 34
  • [40] Possible agent for COVID-19 treatment: Rifampicin
    Ozlem Celik Aydin
    Sonay Ayd?n
    Sureyya Barun
    World Journal of Virology, 2022, 11 (05) : 391 - 393